HRS-4357

Primary Objectives: 1. To evaluate the efficacy of HRS-4357 versus a novel androgen receptor pathway inhibitor (ARPI) in the treatment of PSMA-positive advanced metastatic castration-resistant prostate cancer (mCRPC) using radiographic progression-free survival (rPFS) assessed by a blinded independent imaging review committee (BIRC). Secondary Objectives: 1. To evaluate the efficacy of HRS-4357 versus ARPI in the treatment of PSMA-positive advanced mCRPC using overall survival (OS), investigator-assessed radiographic progression-free survival (rPFS), BIRC and investigator-assessed overall response rate (ORR), disease control rate (DCR), duration of response (DOR), PSA50 response rate, time to PSA progression, and time to first symptomatic bone event (TTSSE). 2. To evaluate patient-reported outcomes of HRS-4357 versus ARPI in the treatment of PSMA-positive advanced mCRPC. 3. To evaluate the safety and tolerability of HRS-4357 versus ARPI in the treatment of PSMA-positive advanced mCRPC.